Exagen Inc. XGN Reportable Segment — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exagen Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exagen Inc.'s reportable segment — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exagen Inc.'s reportable segment — revenue?
- Exagen Inc. (XGN) reported reportable segment — revenue of $17.31M in Q1 2026.
- How has Exagen Inc.'s reportable segment — revenue changed year-over-year?
- Exagen Inc.'s reportable segment — revenue increased by 11.7% year-over-year, from $15.5M to $17.31M.
- What is the long-term trend for Exagen Inc.'s reportable segment — revenue?
- Over 2 years (2023 to 2025), Exagen Inc.'s reportable segment — revenue has grown at a 12.6% compound annual growth rate (CAGR), from $52.55M to $66.58M.
- What does reportable segment — revenue mean?
- The total gross income generated by the reportable segment through the sale of diagnostic testing products and services. It serves as the primary indicator of market demand and the segment's ability to capture share within the autoimmune rheumatic disease diagnostics market.